Lusaris Therapeutics

Lusaris is a biotechnology company advancing a new generation of serotonergic neuroplasticity agents for the treatment of severe neuropsychiatric and neurological disorders. Lusaris’s lead program, LSR-1019, is a proprietary sublingual formulation of 5-MeO-DMT, a fast-acting and rapidly cleared serotonergic psychedelic being developed for treatment-resistant depression and other neuropsychiatric disorders. In addition to LSR-1019, Lusaris’s pipeline includes novel neuroplasticity agents for a broad range of neuropsychiatric and neurological disorders, including migraine and cluster headaches.